NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, announced that effective May 7, 2018 it had moved its corporate domicile from Bermuda to Delaware and changed its name to “Incysus Therapeutics, Inc.”
William Ho, Chief Executive Officer of Incysus said, “This action is part of our strategy to increase the value we deliver to our stakeholders, investors and employees, further improving our competitive position. Much has changed since our founding, including the passage of the Tax Cuts and Jobs Act in December, 2017. As a result, we expect changing our corporate domicile will provide legal, administrative and other similar efficiencies, as well as providing advantages for our corporate development and recruitment strategies. The change of corporate domicile and name will support our growth strategy without affecting the day-to-day business and operations of the organization.”
Mr. Ho continued, “We are excited about the progress we are making and look for 2018 to be a transformative year as we seek to initiate our clinical programs in leukemia and lymphoma patients undergoing haploidentical stem cell transplantation and for the treatment of glioblastoma, an aggressive form of brain cancer.”
About Incysus Therapeutics, Inc.
Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, our technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers. Incysus’ immuno-oncology programs include activated and gene-modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. For more information, visit www.incysus.com.
Incysus Therapeutics, Inc.